|Bid||8.97 x 800|
|Ask||9.45 x 800|
|Day's Range||8.93 - 10.05|
|52 Week Range||5.16 - 15.52|
|Beta (5Y Monthly)||2.11|
|PE Ratio (TTM)||104.07|
|Earnings Date||Feb 03, 2020 - Feb 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Lannett Company, Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Lannett Company, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Pharmaceutical products manufacturer Lannett Company, Inc. (NYSE: LCI) said Monday that its New Drug Application for cocaine hydrochloride nasal solution under the brand name Numbrino has received FDA approval. "The FDA's approval of our Cocaine HCl product, the first NDA approval to include full clinical trials in the company's history, marks a major milestone in Lannett's 70+ years of operations," CEO Tim Crew said in a statement. Numbrino nasal solution is an ester local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for conducting surgeries or diagnostic operations through the nasal cavities of adults.
The drug is the first for which the Northeast Philadelphia company, which focuses primarily on generics, conducted full clinical trials to secure an approval.
Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company's branded local anesthetic product.
Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The estimated IQVIA market values of Venlafaxine ER Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4% are approximately $150 million and $17 million, respectively, for the 12 months ending November 2019, although actual generic market values are expected to be lower.
Lannett Company, Inc. (NYSE: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Butalbital, Acetaminophen and Caffeine (BAC) Capsules, USP, 50mg/300mg/40mg and BAC Capsules, USP, 50 mg/325 mg/40 mg. The two dosage strengths of BAC Capsules, have a combined estimated IQVIA market value of approximately $68.6 million for the 12 months ending October 2019, although actual generic market values are expected to be lower.
Is Lannett Company, Inc. (NYSE:LCI) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their […]
Lannett Company, Inc. (NYSE: LCI) today announced that it expects to commence marketing in the coming months a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets. Adderall XR® including generic versions have an estimated IQVIA market value of approximately $1.3 billion for the 12 months ending October 2019, although actual generic market values are expected to be lower.
Benzinga Pro's Stocks To Watch For Wednesday Salesforce.com (CRM) - Released Q3 EPS and sales results, which beat analyst estimates. The company issued Q4 EPS guidance of $0.54-$0.55, which is below the ...
Shares of Lannett Company Inc. rallied 11% in premarket trading after it said a clinical trial for its experimental long-acting insulin biosimilar met the primary endpoints. Lannett and HEC Group are developing a biosimilar version of Sanofi's Lantus, which has long been the French drugmaker's top-selling drug. Mylan and Biocon are also expected to bring a Lantus biosimilar to market in 2020, although the U.S. application process has slowed since the Food and Drug Administration sent two complete response letters with corrective actions. Lannett's stock has jumped 78% year-to-date, compared to the S&P 500 , which is up 24%.
Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the HEC Group of companies (HEC). Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar.
Moody's Investors Service ("Moody's") affirmed Lannett Company, Inc.'s ("Lannett") B3 Corporate Family Rating and revised the outlook to stable from negative. At the same time, Moody's upgraded the existing senior secured bank credit facilities to B2 from B3 and the Probability of Default Rating (PDR) to B3-PD from Caa1-PD.
It is a pleasure to report that the Lannett Company, Inc. (NYSE:LCI) is up 32% in the last quarter. But will that heal...
Lannett (LCI) delivered earnings and revenue surprises of 10.00% and 4.88%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
PHILADELPHIA , Nov. 6, 2019 /PRNewswire/ -- Financial and Business Highlights: Net Sales, Profitability Exceeded Expectations Launched First-to-Market Posaconazole Expanded Pipeline with Significant ...
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.